AR036566A1 - Vacunas para vih 1 - Google Patents

Vacunas para vih 1

Info

Publication number
AR036566A1
AR036566A1 ARP020103561A ARP020103561A AR036566A1 AR 036566 A1 AR036566 A1 AR 036566A1 AR P020103561 A ARP020103561 A AR P020103561A AR P020103561 A ARP020103561 A AR P020103561A AR 036566 A1 AR036566 A1 AR 036566A1
Authority
AR
Argentina
Prior art keywords
fragment
hiv
nucleotide sequence
epitope
vaccines
Prior art date
Application number
ARP020103561A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2001/004207 external-priority patent/WO2002024225A1/en
Priority claimed from GB0129604A external-priority patent/GB0129604D0/en
Priority claimed from GB0206462A external-priority patent/GB0206462D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR036566A1 publication Critical patent/AR036566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona una secuencia de nucleótidos que codifica una proteína gag de VIH-1 o un fragmento de la misma que contiene un epítopo de gag y un segundo antígeno de VIH o un fragmento que codifica un epítopo de dicho segundo antígeno de VIH, unida operativamente a un promotor heterólogo. Las secuencias de polinucleótido preferidas codifican además nef o un fragmento del mismo y RT o un fragmento de la misma Reivindicación 14: Una composición farmacéutica que comprende una secuencia de nucleótidos de la reivindicación 1 a 11 o un vector de la reivindicación 12 ó 13 y un excipiente, diluyente, vehículo o adyuvante farmacéuticamente aceptable.
ARP020103561A 2001-09-20 2002-09-20 Vacunas para vih 1 AR036566A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2001/004207 WO2002024225A1 (en) 2000-09-20 2001-09-20 Use of immidazoquinolinamines as adjuvants in dna vaccination
GB0129604A GB0129604D0 (en) 2001-12-11 2001-12-11 Novel compounds
GB0206462A GB0206462D0 (en) 2002-03-19 2002-03-19 Vaccines

Publications (1)

Publication Number Publication Date
AR036566A1 true AR036566A1 (es) 2004-09-15

Family

ID=27256076

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103561A AR036566A1 (es) 2001-09-20 2002-09-20 Vacunas para vih 1

Country Status (16)

Country Link
US (2) US20070015721A1 (es)
EP (2) EP2322626A1 (es)
JP (1) JP4601956B2 (es)
CN (1) CN100392085C (es)
AR (1) AR036566A1 (es)
AU (1) AU2002362368B2 (es)
BR (1) BR0212619A (es)
CA (1) CA2461056A1 (es)
CO (1) CO5560591A2 (es)
HU (1) HUP0402259A3 (es)
IL (1) IL160809A0 (es)
MX (1) MXPA04002631A (es)
NO (1) NO331826B1 (es)
NZ (1) NZ531814A (es)
PL (1) PL207168B1 (es)
WO (1) WO2003025003A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003216852B2 (en) * 2002-03-19 2008-09-11 Glaxo Group Limited Imidazoquinolineamines as adjuvants in HIV DNA vaccination
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
AU2012201827B2 (en) * 2005-05-12 2014-09-04 Glaxo Group Limited Vaccine composition
SG182173A1 (en) * 2005-05-12 2012-07-30 Glaxo Group Ltd Vaccine composition
EP2099486A2 (en) * 2006-11-30 2009-09-16 Government Of The United States Of America, As Represented by the Secretary Codon modified immunogenic compositions and methods of use
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
DK2137210T3 (en) 2007-03-02 2017-01-30 Glaxosmithkline Biologicals Sa Hitherto unknown method and compositions
CL2008001491A1 (es) 2007-05-24 2008-11-28 Glaxosmithkline Biolog Sa Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion.
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
EP2485759A4 (en) * 2009-10-09 2013-07-24 Univ New York METHODS, AGENTS AND PEPTIDES FOR INDUCING IMMUNE RESPONSE INNEED IN VACCINATION AGAINST HIV
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PT2772265T (pt) 2010-05-14 2018-04-20 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes e seus usos
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9783823B2 (en) 2013-03-05 2017-10-10 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
AP2017009743A0 (en) 2014-07-16 2017-02-28 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
MA41756A (fr) 2015-02-10 2017-12-20 Fruh Klaus Procédés et compositions utiles dans la génération de réponses non canoniques de lymphocytes t cd8+
JP6873980B2 (ja) 2015-09-14 2021-05-19 ファイザー・インク ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US10532099B2 (en) 2016-10-18 2020-01-14 Oregon Health & Science University Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
EP0500799B1 (en) 1989-11-16 1998-01-14 Duke University Particle mediated transformation of animal skin tissue cells
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5583035A (en) * 1992-12-07 1996-12-10 Bayer Aktiengesellschaft HIV antisense expression vectors
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
AU674815B2 (en) 1994-01-21 1997-01-09 Powderject Vaccines, Inc. Gas driven gene delivery instrument
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
HUP9901112A3 (en) * 1996-02-22 2001-06-28 Merck & Co Inc Synthetic hiv genes
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AP1674A (en) * 1999-11-16 2006-10-30 Geneart Ag The genome of the HIV-1 inter-subtype (C/B') and use thereof.
EP1242441A4 (en) * 1999-12-17 2004-04-14 Merck & Co Inc POLYNUCLEOTIDE VACCINES EXPRESSING CODON-OPTIMIZED NEF HIV-1 PROTEIN AND MODIFIED HIV-1 NEF PROTEIN
MXPA02006379A (es) * 1999-12-23 2004-06-21 Medical Res Council Mejoriasen o relacionadas con la respuesta inmune a vih.
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP1156112B1 (en) * 2000-05-18 2006-03-01 Geneart GmbH Synthetic gagpol genes and their uses
WO2002032943A2 (en) * 2000-08-14 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization

Also Published As

Publication number Publication date
US20090203144A1 (en) 2009-08-13
NZ531814A (en) 2005-10-28
AU2002362368B2 (en) 2006-09-21
PL207168B1 (pl) 2010-11-30
NO20041157L (no) 2004-05-19
EP1427826B1 (en) 2011-04-20
WO2003025003A3 (en) 2003-12-04
CA2461056A1 (en) 2003-03-27
IL160809A0 (en) 2004-08-31
PL370359A1 (en) 2005-05-16
HUP0402259A2 (hu) 2005-01-28
BR0212619A (pt) 2004-08-17
MXPA04002631A (es) 2004-07-08
US20070015721A1 (en) 2007-01-18
EP1427826A2 (en) 2004-06-16
JP4601956B2 (ja) 2010-12-22
JP2005511019A (ja) 2005-04-28
HUP0402259A3 (en) 2010-01-28
CN100392085C (zh) 2008-06-04
CN1606624A (zh) 2005-04-13
CO5560591A2 (es) 2005-09-30
EP2322626A1 (en) 2011-05-18
WO2003025003A2 (en) 2003-03-27
NO331826B1 (no) 2012-04-16

Similar Documents

Publication Publication Date Title
AR036566A1 (es) Vacunas para vih 1
AR050102A1 (es) Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida
AU2003290985B2 (en) West nile virus vaccine
US10556929B2 (en) Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
HU228705B1 (en) Chimeric flavivirus vaccines
US10568956B2 (en) Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
HK1044778A1 (en) Hiv-peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv hiv
US20210100891A1 (en) Compositions and Methods for Generating an Immune Response to a Flavivirus
WO2004050856A3 (en) Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
Brenner et al. Heat shock protein–based therapeutic strategies against human immunodeficiency virus type 1 infection
CR6491A (es) Composiciones y metodos inmunogenicos de hiv
WO2018237039A1 (en) ZIKA VIRAL PSEUDO PARTICLE VACCINE (VLP) VACCINE AND MICRONEUTRALIZATION ASSAY
RU2003128991A (ru) Рекомбинантный поксвирус, кодирующий химерные белки вируса иммунодефицита человека
AR041764A1 (es) Vacuna basada en polinucleotidos y proteinas derivados del vih
Battles et al. Immunological characterization of the gag gene products of bovine immunodeficiency virus
Sato et al. High-level expression of the Japanese encephalitis virus E protein by recombinant vaccinia virus and enhancement of its extracellular release by the NS3 gene product
AU635216B2 (en) Synthetic hiv protease gene and method for its expression
US20050196411A1 (en) Immunogenic HIV compositions and related methods
US7713530B2 (en) HIV-1 subtype isolate regulatory/accessory genes, and modification and derivatives thereof
WO2004016794A1 (en) Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
JPH03271233A (ja) ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
MY131949A (en) Vaccines
CA2998188A1 (en) Cross-reactive t-cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
US20110165190A1 (en) Compositions and Methods for Immunizing Against Immunodeficiency Viruses

Legal Events

Date Code Title Description
FG Grant, registration